论文部分内容阅读
目的 :为了解非霍奇金淋瘤患者外周血粘附分子CD44水平的临床意义。方法 :用流式细胞术检测77例非霍奇金淋巴瘤患者治疗前外周血CD44水平 ,进行临床病理分析并与100例正常人外周血CD44作统计学比较。结果 :正常人PB中CD44为46.14±1.34 ,正常人外周血中CD44与年龄、性别比较无统计学意义。77例非霍奇金淋巴瘤患者外周血CD44与年龄、性别比较也无统计学意义 ,而在淋巴结内淋巴瘤患者、T细胞性淋巴瘤患者、血清乳酸脱氢酶>240U/L患者、Ⅲ期 Ⅳ期及复发患者、有全身症状患者、高度恶性和恶性程度不能区分患者外周血中CD44与正常人比较均有显著性差异(P<0.05)。结论 :非霍奇金淋巴瘤患者外周血CD44水平增高提示与肿瘤原发部位、细胞类型、临床分期、肿瘤分化程度、全身症状、血清乳酸脱氢酶等因素有相关性 ,可为临床提供判断患者预后的参考依据
Objective: To understand the clinical significance of peripheral blood adhesion molecule CD44 in patients with non-Hodgkin’s lymphoma. Methods: Flow cytometry was used to detect the level of CD44 in peripheral blood of 77 non-Hodgkin’s lymphoma patients before and after treatment. The clinicopathological data were compared with those of 100 healthy controls. Results: CD44 in normal PB was 46.14 ± 1.34, while CD44 in peripheral blood of normal people was no significant difference with age and sex. 77 cases of non-Hodgkin’s lymphoma in patients with peripheral blood CD44 and age, sex and no statistical significance, and in patients with lymph node lymphoma, T-cell lymphoma, serum lactate dehydrogenase> 240U / L patients, Ⅲ In stage Ⅳ and relapse patients, patients with systemic symptoms, high degree of malignancy and malignant degree can not distinguish between patients with CD44 and normal people were significantly different (P <0.05). Conclusion: The increased level of CD44 in peripheral blood of patients with non-Hodgkin’s lymphoma is correlated with the primary site of tumor, cell type, clinical stage, degree of tumor differentiation, systemic symptoms, serum lactate dehydrogenase and other factors, which can provide clinical judgment The prognosis of patients with reference